文献速递头颈外科

EREG/AREG表达对西妥昔单抗治疗复发/转移性头颈癌的预后作用

Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab.
PubMed 文献 · Head Neck · 2018-10-10

本研究回顾性分析37例复发/转移性头颈鳞癌患者,检测肿瘤样本中EREG和AREG mRNA表达,评估其与西妥昔单抗联合化疗疗效的关系。结果显示EREG和AREG高表达与显著更长的总生存期和无进展生存期相关,多因素分析中AREG表达与OS和PFS显著相关。提示高表达患者可能从西妥昔单抗联合放化疗中获益更多。

要点

  • EREG和AREG高表达与复发/转移性HNSCC患者更长的OS和PFS显著相关。
  • 多因素分析显示AREG表达与OS和PFS显著相关。
  • EREG/AREG或可作为西妥昔单抗联合化疗疗效的预测预后标志物。

核心结论

  • 复发/转移性HNSCC中EREG和AREG基因高表达患者似乎比低表达患者从西妥昔单抗联合放化疗中获益更多。

研究设计与样本

  • 回顾性分析37例诊断为复发/转移性HNSCC的患者,检测肿瘤样本EREG和AREG mRNA基因表达并评估临床结局。

主要发现

  • EREG和AREG值与显著更长的总生存期相关(分别为P = .03和P = .01)。
  • EREG和AREG值与显著更长的无进展生存期相关(分别为P = .04和P = .04)。
  • 多因素分析显示AREG表达与OS和PFS显著相关。

临床怎么用

  • EREG和AREG mRNA表达或可用于筛选可能从西妥昔单抗联合化疗中获益更多的复发/转移性HNSCC患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cetuximab combined with chemoradiotherapy chemotherapy is the standard therapy for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). However, survival benefit is limited. The purpose of this study was to investigate the expression of epiregulin (EREG) and amphiregulin (AREG), as predictive prognostic markers for the efficacy of cetuximab combined with chemotherapy in R/M HNSCC. METHODS: We conducted a retrospective analysis of 37 patients diagnosed with R/M HNSCC. Tumor samples were analyzed for EREG and AREG mRNA gene expression, and clinical outcomes evaluated. RESULTS: Values of EREG and AREG were associated with significantly longer overall survival (OS) (P = .03 and P = .01, respectively), as well as progression-free survival (PFS) (P = .04 and P = .04, respectively). Multivariate analysis revealed that AREG expression was significantly associated with OS and PFS. CONCLUSIONS: Patients with recurrent/metastatic HNSCC with higher EREG and AREG gene expression appear to benefit more from cetuximab combined with chemoradiotherapy chemotherapy than those with lower expression.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Kogashiwa Y, Inoue H, Kuba K, et al. Prognostic role of epiregulin/amphiregulin expression in recurrent/metastatic head and neck cancer treated with cetuximab. Head Neck. 2018. PMID: 30302873. doi:10.1002/hed.25353

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。